Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Assets (2020 - 2026)

InMed Pharmaceuticals has reported Current Assets over the past 5 years, most recently at $8.8 million for Q4 2025.

  • For Q4 2025, Current Assets rose 60.67% year-over-year to $8.8 million; the TTM value through Dec 2025 reached $8.8 million, up 60.67%, while the annual FY2025 figure was $12.9 million, 48.08% up from the prior year.
  • Current Assets for Q4 2025 was $8.8 million at InMed Pharmaceuticals, down from $10.8 million in the prior quarter.
  • Over five years, Current Assets peaked at $16.0 million in Q3 2021 and troughed at $5.5 million in Q4 2024.
  • A 5-year average of $10.2 million and a median of $10.1 million in 2024 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: plummeted 53.68% in 2024 and later surged 60.67% in 2025.
  • Year by year, Current Assets stood at $12.5 million in 2021, then rose by 12.1% to $14.0 million in 2022, then fell by 15.75% to $11.8 million in 2023, then plummeted by 53.68% to $5.5 million in 2024, then surged by 60.67% to $8.8 million in 2025.
  • Business Quant data shows Current Assets for INM at $8.8 million in Q4 2025, $10.8 million in Q3 2025, and $12.9 million in Q2 2025.